A novel approach based on lipid nanoparticles (SLN®) for topical delivery of α-lipoic acid

References

• Boistelle R. 1988. Fundamentals of nucleation and crystal growth. In: Garti N, Sato K, editors. Crystallization and polymorphism of fats and fatty acids. New York: Marcel Dekker Inc. pp 189–226.
   Google Scholar
• Breitner H. 2003. Randomized, placebo-controlled, double blind study on the clinical efficacy of a cream containing 5% alpha-lipoic acid related to photoageing of facial skin. British Journal of Dermatolology 149:841–849.
   PubMedGoogle Scholar
• Bunjes H, Drechsler M, Koch MFIJ, Westesen K. 2001. Incorporation of the model drug ubidecarenone into solid lipid nanoparticles. Pharmaceutical Research 18:287–293.
   PubMedGoogle Scholar
• Bunjes H, Siekmann B, Westesen K. 1998. Submicron lipid suspensions (solid lipid nanoparticles) versus lipid nanoemulsions: Similarities and differences. In: Benita SE, editor. Submicron emulsions in drug targeting and delivery. Amsterdam: Harwood Academic Publishers. pp 175–204.
   Google Scholar
• Dingier A, Hildebrand G, Niehus H, Mailer RH. 1998. Cosmetic anti-aging formulation based on vitamin E-loaded solid lipid nanoparticles. Proceeding of the 25th International Symposium on Controlled Release Bioactive Materials. pp 433–434.
   Google Scholar
• Eldem T, Speiser P, Altorfer H. 1991a. Polymorphic behavior of sprayed lipid micropellets and its evaluation by differential scanning calorimetry and scanning electron microscopy. Pharmaceutical Research 8:178–184.
   PubMedGoogle Scholar
• Eldem T, Speiser P, Hinkal A. 1991b. Optimization of spray-dried and congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharmaceutical Research 8:47–54.
   PubMedGoogle Scholar
• Freitas C, Muller RH. 1999. Correlation between long-term stability of solid lipid nanoparticles (SLNTM) and crystallinity of the lipid phase. European Pharmaceutics, Biopharmaceutics 47:125–132.
   PubMedGoogle Scholar
• Haak E, Usadel KH, Kusterer K, Amini P, Trischler HJ, Haak J. 2000. Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Experimental and Clinical Endocrinology and Diabetes 108:168–174.
   PubMedGoogle Scholar
• Jenning V. 1999. Feste Lipid-Nanopartikel (SLN) als Trägersystem für die dermale Applilkation von Retinol. PhD thesis, Freie Universität, Berlin.
   Google Scholar
• Kristl J, Volk B, Gagperlin M, entjurc M, Jurkovic P. 2003. Effect of colloidal carriers on ascorbyl palmitate stability. European Pharmaceutics, Biopharmaceutics 19:181–189.
   Google Scholar
• Lippacher A, Muller RH, Mader K. 2000. Investigations on the viscoelastic properties of lipid based colloidal drug carriers. International Journal of Pharmaceutics 196:227–230.
   PubMedGoogle Scholar
• Lippacher A, Muller RH, Mader K. 2001. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. International Journal of Pharmaceutics 214:9–12.
   PubMedGoogle Scholar
• Mehnert W, Mader K. 2001. Solid lipid nanoparticles-production, characterization and applications. Advanced Drug Delivery Reviews 47:165–196.
   PubMedGoogle Scholar
• Mehnert W, zur Mühlen A, Dingier A, Weyhers H, Muller RH. 1997. Solid lipid nanoparticles (SLN)-ein neuartiger Wirkstoff-Carrier far Kosmetika und Pharmazeutika. II. Wirkstoff-Inkorporation, Freisetzung und Sterilizierbarkeit. Pharmazeutische Industrie 59:511–514.
   Google Scholar
• Muller RH, Dingier A, Runge SA, Schneppe T, Gohla S. 2000b. Large scale production of solid lipid nanoparticles (SLNTM) and nanosuspensions (DissoCubesTm). In: Wise D, editor. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker Inc. pp 359–376.
   Google Scholar
• Muller RH, Lucks J-S. 1996. Azneistoffträger aus festen Lipidteilchen-feste Lipid Nanosphdren (SLN). Germany. European Patent 0605497.
   Google Scholar
• Muller RH, Mader K, Gohla S. 2000a. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of art. European Pharmaceutics, Biopharmaceutics 50:161–177.
   PubMedGoogle Scholar
• Muller RH, Mehnert W, Lucks J-S, Schwarz C, zur Mühlen A, Weyhers H, Freitas C, Ruhl D. 1995. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. European Pharmaceutics, Biopharmaceutics 41:62–69.
   Google Scholar
• Mailer RH, Radtke M, Wissing SA. 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (SLN) in cosmetic and dermatological preparations. Advanced Drug Delivery Reviews 54:S131–S155.
   Google Scholar
• Nagamatsu M, Nichander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler H, Low PA. 1995. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18:1160–1167.
   PubMedGoogle Scholar
• Podda M, Zollner TM, Grundmann-Kollmann M, Thiele jj, Packer L, Kaufmann R. 2001. Activity of alpha-lipoic acid in the protection against oxidative stress in skin. Current Problems in Dermatology 29:43–51.
   PubMedGoogle Scholar
• Schleicher ED, Wagner E, Nerlich AG. 1997. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. Journal of Clinical Investigation 99:457–468.
   PubMedGoogle Scholar
• Souto EB, Wissing SA, Barbosa CM, Mailer RH. 2004. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. European Pharmaceutics, Biopharmaceutics 58:83–90.
   PubMedGoogle Scholar
• Venkatraman M, Chittiboyina A, Meingassner J, Ho CI, Varami J, Ellis CN, Avery MA, Pershadsingh HA, Kurtz TW, Benson SC. 2004. A-Lipoic acid-based PPARg agonists for treating inflammatory skin diseases. Archives in Dermatological Research 296:97–104.
   PubMedGoogle Scholar
• Westesen K, Bunjes H. 1995. Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? International Journal of Pharmaceutics 115:129–131.
   Google Scholar
• Westesen K, Bunjes H, Koch MFIJ. 1997. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. Journal of Controlled Release 48:223-236. Wissing SA, Lippacher A, Muller RH. 2001. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). Journal of Cosmetic Science 52:313–324.
   Google Scholar
• Wissing SA, Muller RH. 2001a. A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles. International Journal of Cosmetic Science 23:233–243.
   PubMedGoogle Scholar
• Wissing SA, Muller RH. 2001b. Solid lipid nanoparticles (SLN)-a novel carrier for UV blockers. Die Pharmazie 56:783–786.
   PubMedGoogle Scholar
• Wissing SA, Muller RH. 2001c. Solid lipid nanoparticles (SLN) as sunscreens: Advantages over conventional emulsion based systems. Proceeding of the 28th International Symposium on Controlled Release Bioactive Materials. pp 522–523.
   Google Scholar
• Wissing SA, Muller RH. 2002a. The influence of the crystallinity of lipid nanoparticles on their occlusive properties. International Journal of Pharmaceutics 242:377–379.
   PubMedGoogle Scholar
• Wissing SA, Muller RH. 2002b. The development of an improved carrier system for sunscreens formulations based on crystalline lipid nanoparticles. International Journal of Pharmaceutics 242:373–375.
   PubMedGoogle Scholar
• Wissing SA, Muller RH. 2002c. Solid lipid nanoparticles as carrier for sunscreens: In vitro release and in vivo skin penetration. Journal of Controlled Release 81:225–233.
   PubMedGoogle Scholar
• Wissing SA, Muller RH. 2002d. In vitro and in vivo skin permeation of sunscreens from solid lipid nanoparticles (SLNTm), supercooled melts and emulsions. Proceeding of the 4th World Meeting APGI/APV, Florence. pp 1135–1136.
   Google Scholar